Probing the Dark Sector through Mono-Z Boson Leptonic Decays

Collider search for dark matter production has been performed over the years based on high pT standard model signatures balanced by large missing transverse energy. The mono-Z boson production with leptonic decay has a clean signature with the advantage that the decaying electrons and muons can be precisely measured. This signature not only enables reconstruction of the Z boson rest frame, but also makes possible recovery of the underlying production dynamics through the decaying lepton angular distribution. In this work, we exploit full information carried by the leptonic Z boson decays to set limits on coupling strength parameters of the dark sector. We study simplified dark sector models with scalar, vector, and tensor mediators and observe among them different signatures in the distribution of angular coefficients.Specifically, we show that angular coefficients can be used to distinguish different scenarios of the spin-0 and spin-1 models, including the ones with parity-odd and charge conjugation parity-odd operators. To maximize the statistical power, we perform a matrix element method study with a dynamic construction of event likelihood function. We parametrize the test statistic such that sensitivity from the matrix element is quantified through a term measuring the shape difference. Our results show that the shape differences provide significant improvements in the limits, especially for the scalar mediator models. We also present an example application of a matrix-element-kinematic-discriminator, an easier approach that is applicable for experimental data.Comment: 26 pages, 16 figure

The CERN LHC Sensitivity on measuring WZGamma Production and Anomalous WWZGamma Coupling

In this paper we present for the first time a detailed Monte Carlo study of measuring WZGamma production with pure leptonic decays and probing anomalous quartic gauge-boson WWZGamma couplings at the sqrt(s) = 14 TeV LHC, with parton shower and detector simulation effects taken into account. We find that with an integrated luminosity of 100 fb-1 and proper selection cuts, the Standard Model WZGamma signal significance can be improved to as much as 3 sigma. After reviewing previous parametrization on anomalous WWZGamma couplings (see e.g.an/Lambda^2 or k2m/Lambda^2 as shown in Ref. [17]), we propose a more general parametrization scheme with 4 free inputs leading only to genuine WWZGamma aQGC couplings. Finally, our numerical results show that one can reach constraints at 95% confidence level of -5.7 * 10^{-5} GeV^{-2} < k2m/Lambda^2 < 5.5 * 10^{-5} GeV^{-2} and -2.2 x 10^{-5} GeV^{-2} < an/Lambda^2 < 2.4 * 10^{-5} GeV^{-2}, which are more stringent than LEP's results by three orders of magnitude.Comment: 15 pages, 5 figures. arXiv admin note: text overlap with arXiv:1211.164

Probing Triple-W Production and Anomalous WWWW Coupling at the CERN LHC and future 100TeV proton-proton collider

Triple gauge boson production at the LHC can be used to test the robustness of the Standard Model and provide useful information for VBF di-boson scattering measurement. Especially, any derivations from SM prediction will indicate possible new physics. In this paper we present a detailed Monte Carlo study on measuring WWW production in pure leptonic and semileptonic decays, and probing anomalous quartic gauge WWWW couplings at the CERN LHC and future hadron collider, with parton shower and detector simulation effects taken into account. Apart from cut-based method, multivariate boosted decision tree method has been exploited for possible improvement. For the leptonic decay channel, our results show that at the sqrt{s}=8(14)[100] TeV pp collider with integrated luminosity of 20(100)[3000] fb-1, one can reach a significance of 0.4(1.2)[10]sigma to observe the SM WWW production. For the semileptonic decay channel, one can have 0.5(2)[14]sigma to observe the SM WWW production. We also give constraints on relevant Dim-8 anomalous WWWW coupling parameters.Comment: Accepted version by JHE

Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer

PURPOSE: The purpose of this study was to evaluate longitudinal changes in brain gray matter density (GMD) before and after adjuvant chemotherapy in older women with breast cancer. METHODS: We recruited 16 women aged ≥ 60 years with stage I-III breast cancers receiving adjuvant chemotherapy (CT) and 15 age- and sex-matched healthy controls (HC). The CT group underwent brain MRI and the NIH Toolbox for Cognition testing prior to adjuvant chemotherapy (time point 1, TP1) and within 1 month after chemotherapy (time point 2, TP2). The HC group underwent the same assessments at matched intervals. GMD was evaluated with the voxel-based morphometry. RESULTS: The mean age was 67 years in the CT group and 68.5 years in the HC group. There was significant GMD reduction within the chemotherapy group from TP1 to TP2. Compared to the HC group, the CT group displayed statistically significantly greater GMD reductions from TP1 to TP2 in the brain regions involving the left anterior cingulate gyrus, right insula, and left middle temporal gyrus (pFWE(family-wise error)-corrected < 0.05). The baseline GMD in left insula was positively correlated with the baseline list-sorting working memory score in the HC group (pFWE-corrected < 0.05). No correlation was observed for the changes in GMD with the changes in cognitive testing scores from TP1 to TP2 (pFWE-corrected < 0.05). CONCLUSIONS: Our findings indicate that GMD reductions were associated with adjuvant chemotherapy in older women with breast cancer. Future studies are needed to understand the clinical significance of the neuroimaging findings. This study is registered on ClinicalTrials.gov (NCT01992432)

Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers

Background: Older adults (≥65 years) with gastrointestinal (GI) cancers who receive chemotherapy are at increased risk of hospitalization caused by treatment-related toxicity. Geriatric assessment (GA) has been previously shown to predict risk of toxicity in older adults undergoing chemotherapy. However, studies incorporating the GA specifically in older adults with GI cancers have been limited. This study sought to identify GA-based risk factors for chemotherapy toxicity-related hospitalization among older adults with GI cancers. Patients and methods: We performed a secondary post hoc subgroup analysis of two prospective studies used to develop and validate a GA-based chemotherapy toxicity score. The incidence of unplanned hospitalizations during the course of chemotherapy treatment was determined. Results: This analysis included 199 patients aged ≥65 years with a diagnosis of GI cancer (85 colorectal, 51 gastric/esophageal, and 63 pancreatic/hepatobiliary). Sixty-five (32.7%) patients had ≥1 hospitalization. Univariate analysis identified sex (female), cardiac comorbidity, stage IV disease, low serum albumin, cancer type (gastric/esophageal), hearing deficits, and polypharmacy as risk factors for hospitalization. Multivariable analyses found that patients who had cardiac comorbidity (OR 2.48, 95% CI 1.13-5.42) were significantly more likely to be hospitalized. Conclusion: Cardiac comorbidity may be a risk factor for hospitalization in older adults with GI cancers receiving chemotherapy. Further studies with larger sample sizes are warranted to examine the relationship between GA measures and hospitalization in this vulnerable population

Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study

Purpose Older cancer patients are at increased risk of cancer-related cognitive impairment. The purpose of this study was to assess the alterations in intrinsic brain activity associated with adjuvant chemotherapy in older women with breast cancer. Methods Chemotherapy treatment (CT) group included sixteen women aged ≥ 60 years (range 60–82 years) with stage I-III breast cancers, who underwent both resting-state functional magnetic resonance imaging (rs-fMRI) and neuropsychological testing with NIH Toolbox for Cognition before adjuvant chemotherapy, at time point 1 (TP1), and again within 1 month after completing chemotherapy, at time point 2 (TP2). Fourteen age- and sex-matched healthy controls (HC) underwent the same assessments at matched intervals. Three voxel-wise rs-fMRI parameters: amplitude of low-frequency fluctuation (ALFF), fractional ALFF (fALFF), and regional homogeneity (ReHo), were computed at each time point. The changes in rs-fMRI parameters from TP1 to TP2 for each group, the group differences in changes (the CT group vs. the HC group), and the group difference in the baseline rs-fMRI parameters were assessed. In addition, correlative analysis between the rs-fMRI parameters and neuropsychological testing scores was also performed. Results In the CT group, one brain region, which included parts of the bilateral subcallosal gyri and right anterior cingulate gyrus, displayed increased ALFF from TP1 to TP2 (cluster p-corrected=0.024); another brain region in the left precuneus displayed decreased fALFF from TP1 to TP2 (cluster level p-corrected=0.025). No significant changes in the rs-fMRI parameters from TP1 to TP2 were observed in the HC group. Although ALFF and fALFF alterations were observed only in the CT group, none of the between-group differences in rs-fMRI parameter changes reached statistical significance. Conclusions Our study results of ALFF and fALFF alterations in the chemotherapy-treated women suggest that adjuvant chemotherapy may affect intrinsic brain activity in older women with breast cancer

Effects of chemotherapy on aging white matter microstructure: a longitudinal diffusion tensor imaging study

Objective: We aimed to use diffusion tensor imaging (DTI) to detect alterations in white matter microstructure in older patients with breast cancer receiving chemotherapy. Methods: We recruited women age ≥60 years with stage I-III breast cancer (chemotherapy [CT] group; n = 19) to undergo two study assessments: at baseline and within one month after chemotherapy. Each assessment consisted of a brain magnetic resonance imaging scan with DTI and neuropsychological (NP) testing using the National Institutes of Health (NIH) Toolbox Cognition Battery. An age- and sex-matched group of healthy controls (HC, n = 14) underwent the same assessments at matched intervals. Four DTI parameters (fractional anisotropy [FA], mean diffusivity [MD], axial diffusivity [AD], and radial diffusivity [RD]) were calculated and correlated with NP testing scores. Results: For CT group but not HCs, we detected statistically significant increases in MD and RD in the genu of the corpus callosum from time point 1 to time point 2 at p 0.05). Conclusions: We identified alterations in white matter microstructures in older women with breast cancer undergoing chemotherapy. These findings may potentially serve as neuroimaging biomarkers for identifying cognitive impairment in older adults with cancer